VGEN Financials 07/16/2014 07:55:06 Vaccinogen, I

VGEN Financials 07/16/2014 07:55:06
Vaccinogen, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Total Revenue - - -
Cost of Revenue - - -
Gross Profit - - -
Operating Expenses
Research and Development 8,687 8,139 8,565
Sales, General and Admin. 10,756 2,961 2,783
Non-Recurring Items - - -
Other - - -
Operating Income (19,444) (11,100) (11,348)
Income From Continuing Operations
Add'l Income/Expense Items (3,075) (1,282) -
Earnings Before Interest and Tax (22,518) (12,382) (11,348)
Interest Expense 2,062 312 176
Earnings Before Tax (24,581) (12,694) (11,524)
Income Tax - - -
Minority Interest - - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (24,581) (12,694) (11,524)
Non Recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (24,581) (12,694) (11,524)
Preferred Stock and Other Adjustments - (16,518) (27,668)
Net Income Applicable to Common Shareholders (24,581) (29,212) (39,192)